| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Pelthos Therapeutics Inc. | CEO and President, Director | Stock Option | 255,000 | 02 Jul 2025 | Direct | ||
| Pelthos Therapeutics Inc. | CEO and President, Director | Restricted Stock Units | 83,678 | 02 Jul 2025 | Direct | ||
| BIODELIVERY SCIENCES INTERNATIONAL INC | President and Chief Commercial Officer | Common Stock | 0 | $1.80 | 22 Mar 2022 | Direct | |
| BIODELIVERY SCIENCES INTERNATIONAL INC | President and Chief Commercial Officer | Restricted Stock Units | 0 | 22 Mar 2022 | Direct | ||
| BIODELIVERY SCIENCES INTERNATIONAL INC | President and Chief Commercial Officer | Stock Options (right to buy) | 0 | $3.66 | 22 Mar 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CHRO | Pelthos Therapeutics Inc. | 02 Jul 2025 | 2 | $0 | 4 | CEO and President, Director | 23 Jul 2025, 21:17 |
| CHRO | Pelthos Therapeutics Inc. | 02 Jul 2025 | 0 | $0 | 3 | CEO and President, Director | 23 Jul 2025, 21:14 |
| /report/000110302122000070-plesha-scott-m-2022-03-22 | BIODELIVERY SCIENCES INTERNATIONAL INC | 22 Mar 2022 | 5 | $0 | 4 | President and Chief Commercial Officer | 22 Mar 2022, 17:14 |
| /report/000110302122000016-plesha-scott-m-2022-01-27 | BIODELIVERY SCIENCES INTERNATIONAL INC | 27 Jan 2022 | 8 | +$1,353,179 | 4 | President and Chief Commercial Officer | 31 Jan 2022, 16:56 |